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1 It has previously been shown that the antimigraine drug sumatriptan constricts porcine carotid
arteriovenous anastomoses via 5-HT1-like receptors, identical to 5-HT1B/1D receptors. The recent
availability of silent antagonists selective for the 5-HT1B (SB224289) and 5-HT1D (BRL15572)
receptor led us to further analyse the nature of receptors involved.
2 In pentobarbitone-anaesthetized, bilaterally vagosympathectomized pigs, sumatriptan (30, 100
and 300 mg kg71, i.v.) dose-dependently decreased carotid arteriovenous anastomotic conductance
by up to 70+5%.
3 The dose-related decreases in carotid arteriovenous anastomotic conductance by sumatriptan (30,
100 and 300 mg kg71, i.v.) remained unchanged in animals treated (i.v.) with 1 mg kg71 of
BRL15572 (maximum decrease: 72+3%), but were significantly attenuated by 1 mg kg71
(maximum decrease: 30+11%) and abolished by 3 mg kg71 (maximum decrease: 3+7%) of
SB224289. The highest dose of SB224289 did not attenuate the hypertension, tachycardia or
increases in carotid blood flow induced by bolus injections of noradrenaline (0.1 – 3 mg kg71, i.v.).
4 The results indicate that sumatriptan constricts porcine carotid arteriovenous anastomoses
primarily via 5-HT1B, but not via 5-HT1D receptors.
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Abbreviations: A-V SO2, Dierence between oxygen saturation of arterial and jugular venous blood; BRL15572, 1-(3-
chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride; GR127935, (N-[4-Methoxy-
3-(4-methyl-1-piperazinyl)phenyl]-2'methyl-4' (5-methyl-1, 2,4- oxadiazol- 3-yl) [1,1,-biphenyl]-4-carboxamide
hydrochloride monohydrate); SB224289, 2,3,6,7-tetrahydro-1'-methyl-5-[2'methyl-4'5-(methyl-1,2,4-oxadiazol-3-
yl) biphenyl-4-carbonyl] furo [2,3-f] indole-3-spiro-4'-piperidine hydrochloride; SKF-99101H, 3-(2-dimethylami-
noethyl)-4-chloro-5-propoxyindole hemifumarate
Introduction
It has previously been shown in several species that 5-HT
causes constriction within the carotid vascular bed predomi-
nantly via 5-HT1-like receptors and this eect is potently
mimicked by the antimigraine drug, sumatriptan (Den Boer et
al., 1991; Villalo´n et al., 1995). The carotid vasoconstrictor
eect of sumatriptan and other acutely acting antimigraine
agents is exclusively due to vasoconstriction of carotid
arteriovenous anastomoses (see Saxena et al., 1997b; De Vries
et al., 1999), which may open up during migraine headaches
(Heyck, 1969; Saxena, 1995). Since sumatriptan displayed high
anity at the 5-HT1D receptor binding sites identified in calf
and human caudate membranes (see Hoyer et al., 1994;
Martin, 1994), it was suggested that ‘5-HT1D’ receptors were
responsible for the sumatriptan-induced carotid vasoconstric-
tion. Presently, we know that the experimental conditions in
the above experiments allowed the inclusion of 5-HT1B, 5-
HT1D as well as 5-ht1F receptors (see Saxena et al., 1998).
GR127935 (N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-
2'-methyl-4' (5-methyl-1, 2,4-oxadiazol- 3-yl) [1,1,-biphenyl]-
4-carboxamide hydrochloride monohydrate), the first potent
and selective antagonist at the ‘5-HT1D’ receptor (Clitherow et
al., 1994; Pauwels, 1996; Skingle et al., 1996), was shown to
inhibit the sumatriptan-induced carotid vasoconstriction in
pigs (De Vries et al., 1996) and dogs (Villalo´n et al., 1996). In
the mean time, it was demonstrated that the human 5-HT1D
receptor was encoded by two structurally distinct genes, named
5-HT1Da and 5-HT1Db (Weinshank et al., 1992). The 5-HT1Da
receptor was shown to be the human homologue of the rat 5-
HT1B receptor and, consequently, renamed 5-HT1B, while the
5-HT1Da receptor was renamed 5-HT1D receptor (see Hartig et
al., 1996). Unfortunately, GR127935 was not able to
distinguish between these 5-HT1B and 5-HT1D receptors (Table
1). Recently, however, two new potent compounds were
developed, SB224289 (2,3,6,7-tetrahydro-1'-methyl-5-[2'-
methyl-4'(5-methyl-1,2,4-oxadiazol-3-yl) biphenyl-4-carbonyl]
furo [2,3-f] indole-3-spiro-4'-piperidine hydrochloride; Gaster
et al., 1998) and BRL15572 (1-(3-chlorophenyl)-4-[3,3-diphe-
nyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride;
Price et al., 1997), which show a high degree of selectivity for
the 5-HT1B and 5-HT1D receptor, respectively (Table 1). Using
these compounds, it was shown that sumatriptan-induced
canine external carotid vasoconstriction (De Vries et al.,
1998a) and human isolated temporal artery contraction
(Verheggen et al., 1998) as well as hypothermia induced by
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yindole hemifumarate) in the guinea-pig (Hagan et al., 1997)
are mediated by SB224289-sensitive 5-HT1B receptors, whereas
the human atrium heteroreceptor resembles BRL15572-
sensitive 5-HT1D receptors (Schlicker et al., 1997). In the light
of the availability of the above selective ligands, we decided to
verify whether 5-HT1B or 5-HT1D receptors are involved in the
constriction of carotid arteriovenous anastomoses in anaes-
thetized pigs by the antimigraine drug, sumatriptan.
Methods
General
After an overnight fast, 21 pigs (Yorkshire x Landrace; 10 –
15 kg) were anaesthetized with azaperone (160 mg, i.m.),
midazolan hydrochloride (5 mg, i.m.) and pentobarbitone
sodium (600 mg, i.v.), intubated and connected to a respirator
(BEAR 2E, BeMeds AG, Baar, Switzerland) for intermittent
positive pressure ventilation with a mixture of room air and
oxygen. Respiratory rate, tidal volume and oxygen supply were
adjusted to keep arterial blood gas values within physiological
limits (pH: 7.35 – 7.48; pCO2: 35 – 48 mmHg; pO2:100 –
120 mmHg). Anaesthesia was maintained with a continuous
i.v. infusion of pentobarbitone sodium at 20 mg kg71 min71.
With this anaesthetic regimen, arteriovenous anastomotic
blood flow is considerably higher than that in pigs in a
conscious state or under thiopentone anaesthesia (Den Boer et
al., 1993), thereby producing one of the main putative features
of migraine, i.e. vasodilatation of carotid arteriovenous
anastomoses (see Heyck, 1969; Saxena, 1995).
Catheters were placed in the inferior vena cava via the left
femoral vein for the administration of drugs and in the aortic
arch via the left femoral artery for the measurement of arterial
blood pressure (Combitrans disposable pressure transducer;
Braun, Melsungen, Germany) and the withdrawal of arterial
blood for determining blood gases (ABL-510, Radiometer,
Copenhagen, Denmark). The common carotid arteries,
external jugular veins and vagus nerves were identified and
both vagi and the accompanying cervical sympathetic nerves
were cut between two ligatures, in order to avoid reflex-
mediated changes in the carotid vasculature. Another catheter
was placed in the right external jugular vein for the withdrawal
of venous blood samples, while the right common carotid
artery was dissected free and a needle was inserted against the
direction of blood flow for the administration and uniform
Table 1 pKi values of sumatriptan, SB24289, BRL15572
and GR127935 at human cloned 5-HT1 receptor subtypes
5-HT1A 5-HT1B 5-HT1D 5-ht1E 5-ht1F
Sumatriptana
GR127935c
SB224289b
BRL15572c
6.4
7.2
55.5
7.7
7.8
9.0
8.2
6.1
8.5
8.6
6.3
7.9
5.8
5.4
55.0
5.2
7.9
6.4
55.0
6.0
aLeysen et al. (1996); bGaster et al. (1998); cPrice et al.
(1997).
Table 3 Systematic haemodynamic eects of sequential doses of sumatriptan in pigs treated with vehicle (n=6), SB224289 (1 or
3 mg kg71; n=6 or 3, resepectively) or BRL15572 (n=6)
Sumatriptan (mg kg71, i.v.)
Treatment Baseline 30 100 300
Heart rate (beat min71)
Vehicle
SB224289 (1 mg kg71)
SB224289 (3 mg kg71)
BRL15572 (1 mg kg71)
93+2
101+2
103+7
99+3
91+2*
100+2
102+6
98+3
90+2*
98+2*
100+5*
96+3*
89+2*
96+2*
99+5*
94+4*
Mean arterial blood pressure (mmHg)
Vehicle
SB224289 (1 mg kg71)
SB224289 (3 mg kg71)
BRL15572 (1 mg kg71)
103+3
105+4
96+6
92+3
103+4
94+6*,+
88+7+
92+2
103+4
90+5*,+
81+3*,+
90+3
97+5*
86+5*,+
81+2*
85+4*
Arterial-jugular venous oxygen saturation dierence (%)
Vehicle
SB224289 (1 mg kg71)
SB224289 (3 mg kg71)
BRL15572 (1 mg kg71)
5.1+0.8
6.9+1.4
10.0+4.7
9.4+3.7
7.0+0.8
12.1+2.8*
10.3+2.7
10.8+3.4
11.4+2.6*
12.1+3.3*
8.4+3.7
14.8+5.0*
17.7+2.8*
14.9+2.2*
10.0+4.2+
18.6+4.8*
All values have been presented as mean+s.e.mean. *P50.05 vs baseline. +P50.05 vs response by corresponding dose of sumatriptan
in animals treated with vehicle.
Table 2 The eects of (i.v.) vehicle, SB224289 and BRL15572 on systemic and carotid haemodynamics in vagosympathectomized pigs
Vehicle (n=6) SB224289 (1 mg kg71; n=6) SB224289 (3 mg kg71; n=3) BRL15572 (1 mg kg71; n=6)
Before After Before After Before After Before After
HR
MAP
A-V SO2
Total carotid VC
AVA VC
Nutrient VC
93+3
105+1
5.6+0.8
116+6
92+7
24+4
93+2
103+3
51.+0.7
118+6
89+7
29+3
100+2
94+2
8.5+1.8
138+10
109+10
29+3
101+2
105+4*
6.9+1.4
122+13
88+13*
35+3
101+6
89+2
10.8+3.8
201+44
149+35
51+10
103+7
96+6
10.0+4.7
174+29
119+20
55+10
100+3
90+2
9.1+3.5
124+7
87+8
37+5
99+3
92+3
9.4+3.7
123+8
86+8
37+4
All values have been presented as mean+s.e.mean. *P50.05 after vs before. HR, heart rate (beats min71); MAP, mean arterial blood
pressure (mmHg); A-V SO2 arteriolar-jugular venous oxygen saturation dierence (%); VC, vascular conductance
(1072 ml min71 mmHg71); AVA, anteriovenous anastomotic. The eects of vehicle or the antagonists were measured 15 min after
administration.
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mixing of radioactive microspheres. Blood flow was measured
in the right common carotid artery with a flow probe (internal
diameter: 2.5 mm) connected to a sine-wave electromagnetic
flow meter (Transflow 601-system, Skalar, Delft, The Nether-
lands). Heart rate was measured with a tachograph (CRW,
Erasmus University, Rotterdam, The Netherlands) triggered
by electrocardiographic signals.
Arterial blood pressure, heart rate and carotid blood flow
were continuously monitored on a polygraph (CRW, Erasmus
University, Rotterdam, The Netherlands). Body temperature
was kept at about 378C and the animals were continuously
infused with saline to compensate for fluid losses during the
experiment. The Ethics Committee of the Erasmus University
Rotterdam dealing with the use of animals in scientific
experiments approved the protocol for this investigation.
Distribution of carotid blood flow
The distribution of common carotid blood flow was
determined with 15.5+0.1 (s.d.) mm diameter microspheres
labelled with either 141Ce, 113Sn, 103Ru, 95Nb or 46Sc (NEN
Dupont, Boston, U.S.A.). For each measurement a suspension
of about 200,000 microspheres, labelled with one of the
isotopes, was mixed and injected into the carotid artery. At the
end of the experiment, the animal was killed, using an overdose
of pentobarbitone sodium, and the heart, kidneys, lungs and
the dierent cranial tissues were dissected out, weighed and put
in vials. The radioactivity in these vials was counted for 5 min
in a g-scintillation counter (Packard, Minaxi autogamma
5000), using suitable windows for discriminating the dierent
isotopes (141Ce: 120 – 167, KeV, 113Sn: 355 – 435 KeV, 103Ru:
450 – 548 KeV, 95Nb: 706 – 829 KeV and 46Sc: 830 – 965 KeV).
All data were processed by a set of specially designed programs
(Saxena et al., 1980), using a personal computer.
The fraction of carotid blood flow distributed to the
dierent tissues was calculated by multiplying the ratio of
tissue and total radioactivities by the total common carotid
blood flow at the time of the injection of microspheres. Since
little or no radioactivity was detected in the heart and kidneys,
all microspheres trapped in lungs reached this tissue from the
venous side after escaping via carotid arteriovenous anasto-
moses. Therefore, the amount of radioactivity in the lungs was
used as an index of the arteriovenous anastomotic fraction of
carotid blood flow (Saxena & Verdouw, 1982). Vascular
conductance was calculated by dividing blood flow (ml min71)
by blood pressure (mmHg), multiplied by hundred and
expressed as 1072 ml min71 mmHg71.
Experimental protocol
After a stabilization period of about 1 h, baseline values of
heart rate, mean arterial blood pressure, carotid blood flow
and its distribution, as well as arterial and jugular venous
blood gases were determined. At this point the animals were
divided into four groups, receiving an i.v. infusion (1 ml min71
over a period of 5 min) of either vehicle (distilled water, 20%
propylene glycol, v v71; n=6), SB224289 (1 mg kg71; n=6),
SB224289 (3 mg kg71; n=3) or BRL15572 (1 mg kg71; n=6).
After a waiting period of 15 min, all parameters were
reassessed. Subsequently, sequential i.v. doses of sumatriptan
(30, 100 and 300 mg kg71) were given to all animals every
20 min. Fifteen minutes after each dose of sumatriptan, all
haemodynamic variables were assessed again. In the group
treated with 3 mg kg71 of SB224289, i.v. bolus injections of
noradrenaline (0.1, 0.3, 1 and 3 mg kg71) were given at the
start of the experiment (before SB224289) and at the end of the
experiment (after SB224289 and the three doses of suma-
triptan).
Data presentation and statistical analysis
All data have been expressed as mean+s.e.mean. The
significance of the dierence between the variables within one
group was evaluated with Duncan’s new multiple range test,
once an analysis of variance (randomized block design) had
revealed that the samples represented dierent populations
(Steel & Torrie, 1980). The per cent changes caused by
sumatriptan in animals treated with SB224289 or BRL15572
were compared to the corresponding responses in animals
treated with vehicle by using Student’s unpaired t-test. The
peak changes induced by noradrenaline before and after
3 mg kg71 of SB224289 were compared by Student’s paired t-
test. Statistical significance was accepted at P50.05 (two-
tailed).
Drugs
Apart from the anaesthetics, azaperone (Janssen Pharmaceu-
ticals, Beerse, Belgium), midazolan hydrochloride (Homann
La Roche b.v., Mijdrecht, The Netherlands) and pentobarbi-
tone sodium (Apharmo, Arnhem, The Netherlands), the
compounds used in this study were: sumatriptan succinate
(gift from Dr H.E. Connor, Glaxo Group Research,
Stevenage, Hertfordshire, U.K.), SB224289 and BRL15572
Figure 1 Values of total carotid, arteriovenous anastomotic (AVA)
and nutrient blood flows (left panels) and conductances (right panels)
at baseline and after sumatriptan (30, 100 and 300 mg kg71, i.v.) in
animals treated i.v. with vehicle (Veh; n=6), 1 mg kg71 of SB224289
(SB1; n=6), 3 mg kg71 of SB224289 (SB3; n=3) or BRL15572
(BRL; 1 mg kg71; n=6). All values are presented as mean+
s.e.mean. *P50.05 vs baseline. +P50.05 vs response by correspond-
ing dose in vehicle-treated animals.
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(both gifts from Dr A.A. Parsons, SmithKline Beecham
Pharmaceuticals, Harlow, Essex, U.K.) and noradrenaline
bitatrate (Sigma Chemical Co., St. Louis, Mo., U.S.A.). All
compounds were dissolved in distilled water; when needed
20% (v v71) propylene glycol (SB224289 and BRL15572) was
added. Heparin sodium (Leo Pharmaceutical Products, Weesp,
The Netherlands) was used to prevent clotting of the catheters.
All doses refer to the respective salts.
Results
Systemic and carotid haemodynamic eects by vehicle,
SB224289 or BRL15572
The eects of the two antagonists and vehicle on systemic
(mean arterial blood pressure and heart rate) and carotid
(total, arteriovenous anastomotic and nutrient vascular
conductances and the dierence between oxygen saturation of
arterial and jugular venous blood; A-V SO2) are shown in
Table 2. Except for a moderate, but significant increase in
mean arterial blood pressure (12+2%) and decrease in carotid
arteriovenous anastomotic conductance (21+5%) after the
1 mg kg71, i.v. dose of SB224289, there were no changes in
these variables.
Systemic haemodynamic eects of sumatriptan in pigs
treated with vehicle, SB224289 or BRL15572
Systemic haemodynamic changes induced by sumatriptan in
the four dierent treatment groups are depicted in Table 3. In
vehicle-treated animals, sumatriptan slightly decreased heart
rate (maximum decrease: 4+1%) and blood pressure
(maximum decrease: 7+3%). The sumatriptan-induced bra-
dycardia was not aected by treatment with either SB224289
(maximum decreases after 1 or 3 mg kg71: 5+1% or 4+1%,
respectively) or BRL15572 (maximum decrease: 5+2%). On
the other hand, after treatment with 1 mg kg71 of SB224289,
sumatriptan produced a significantly more pronounced
hypotension (maximum decrease: 19+3%). Similarly,
3 mg kg71 of SB224289 significantly potentiated the hypoten-
sion induced by 30 and 100 mg kg71 of sumatriptan.
Treatment with BRL15572 (1 mg kg71) did not aect the
sumatriptan-induced decrease in blood pressure (maximum
decrease: 7+5%).
Sumatriptan dose-dependently increased A-V SO2 by up to
270+71%. The increases in A-V SO2 by sumatriptan were not
significantly modified by treatment with 1 mg kg71 of
SB224289 or BRL15572 (maximum increases: 161+55 and
151+38%, respectively), whereas after 3 mg kg71 of
SB224289 this eect was absent.
Carotid haemodynamic eects of sumatriptan in pigs
treated with vehicle, SB224289 or BRL15572
Changes in carotid haemodynamics by sumatriptan in the
four dierent groups are depicted in Figures 1 (absolute
values) and 2 (per cent changes). In vehicle-treated animals,
sumatriptan dose-dependently decreased total carotid blood
flow and conductance by up to 44+7% and 40+7%,
respectively, accompanied by decreases in arteriovenous
anastomotic blood flow and conductance by up to 72+4%
and 70+5%, respectively. Nutrient blood flow and con-
ductance increased after sumatriptan by up to 55+25% and
Figure 2 Eect (% change from baseline values) of sumatriptan (30, 100 and 300 mg kg71, i.v.) on total carotid, arteriovenous
anastomotic (AVA) and nutrient conductances in animals treated with vehicle (n=6), 1 mg kg71 of SB224289 (n=6), 3 mg kg71 of
SB224289 (n=3) or BRL15572 (1 mg kg71; n=6). All values are presented as mean+s.e.mean. +P50.05 vs response by
corresponding dose in vehicle-treated animals.
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65+26%, respectively. These eects of sumatriptan were
dose-dependently reduced by SB224289. Thus, in animals
treated with 1 mg kg71 of SB224289 the sumatriptan-induced
decreases in total carotid blood flow and conductance
amounted to only 32+6% and 17+7%, respectively, while
carotid arteriovenous anastomotic blood flow and conduc-
tance decreased by only up to 43+9% and 30+11%,
respectively. After the higher dose (3 mg kg71) of SB224289,
the sumatriptan-induced maximal decreases in total carotid
and arteriovenous anastomotic blood flows (12+7% and
18+3%, respectively) and conductances (4+12% and
3+7%, respectively) were completely blocked. Treatment
with BRL15572 (1 mg kg71) did not aect the sumatriptan-
induced decreases in total carotid and arteriovenous
anastomotic blood flows (maximum decreases: 37+3% and
74+3%, respectively) and conductances (maximum de-
creases: 32+5% and 72+3%, respectively). Neither
SB224289 nor BRL15572 significantly aected the increases
in nutrient blood flow and conductance.
Eect of SB224289 on noradrenaline-induced changes in
heart rate, mean arterial blood pressure and total carotid
blood flow and conductance
As shown in Figure 3, bolus injections of noradrenaline (0.1 –
3 mg kg71, i.v.) produced dose-dependent increases (with
maximum changes) in heart rate (+82+7%), mean arterial
blood pressure (+31+2%) and total carotid blood flow
(+26+5%) without aecting total carotid vascular con-
ductance (maximum change: +4+1%). The maximum
changes by noradrenaline remained either unchanged (heart
rate, 76+3%; mean arterial blood pressure, 43+4%; total
carotid vascular conductance, 5+4%) or were even enhanced
(total carotid blood flow, 47+8%) after SB224289
(3 mg kg71, i.v.).
Discussion
General
We have previously shown that sumatriptan decreases porcine
carotid blood flow by a selective vasoconstriction of cranial
arteriovenous anastomoses (Den Boer et al., 1991). The drug
seems to exert this response via 5-HT1B/1D receptors, since
GR127935, a selective antagonist at these 5-HT1 receptor
subtypes (Clitherow et al., 1994; Pauwels, 1996; Skingle et al.,
1996), was able to abolish the sumatriptan-induced responses
(De Vries et al., 1996). The recent availability of silent selective
antagonists for the 5-HT1B (SB224289) and 5-HT1D
(BRL15572) receptors led us to further analyse the nature of
the receptors mediating these responses. The present study in
anaesthetized pigs clearly showed that the sumatriptan-
induced carotid arteriovenous anastomotic constriction was
potently and specifically antagonized in a dose-dependent
manner by the selective 5-HT1B receptor antagonist SB224289,
but not by the selective 5-HT1D receptor antagonist
BRL15572. Apart from the implications discussed below,
these data indicate that the vasoconstrictor response to
sumatriptan on porcine carotid arteriovenous anastomoses is
mainly mediated by 5-HT1B receptors.
Systemic and carotid haemodynamic eects of vehicle,
SB224289 and BRL15572
Statistically significant changes were noticed only in the group
that received the lower dose (1 mg kg71) of SB224289. A
moderate increase in mean arterial blood pressure and a
vasoconstrictor eect in the carotid vasculature, confined to
the arteriovenous anastomotic fraction, was observed. We do
not have a clear explanation for this, but it is interesting to
note that the 5-HT1B/1D receptor antagonist GR127935 also
Figure 3 Eect (% change from baseline values) of noradrenaline (0.1, 0.3, 1 and 3 mg kg71, i.v.) on heart rate, mean arterial
blood pressure (MAP), carotid blood flow (CaBF) and carotid vascular conductance (CaVC) before and after SB224289
(3 mg kg71, i.v.). All values are presented as mean+s.e.mean. +P50.05 after vs before.
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constricts porcine arteriovenous anastomoses, but, in contrast
to SB224289, decreases blood pressure (De Vries et al., 1996).
Whereas the GR127935-induced carotid vasoconstriction may
be related to its intrinsic activity at the h5-HT1B receptor
(Pauwels, 1996; Selkirk et al., 1998), this seems unlikely in the
case of SB224289, because this compound rather behaves as an
inverse agonist at this receptor (Selkirk et al., 1998).
Systemic haemodynamic eects induced by sumatriptan
in animals treated with vehicle, SB224289 or BRL15572
Sumatriptan caused a small bradycardiac and hypotensive
eect, similar to that reported earlier (De Vries et al., 1996).
This seems to be a class eect, since several other triptans also
display this property (Saxena et al., 1997a; De Vries et al.,
1998b; Willems et al., 1998). The mechanism involved in the
hypotensive and bradycardiac action of sumatriptan is not
clear, but may involve sympathoinhibition either at the level of
ganglia, neurovascular junction (Jones et al., 1995; Villalo´n et
al., 1998) or perhaps within the central nervous system (see
Saxena & Villalo´n, 1990); the latter mechanism seems unlikely
on the basis of poor central penetration of sumatriptan. The
hypotensive response to sumatriptan was unaected by
GR127935 (De Vries et al., 1996), but potentiated by the 5-
HT1B receptor antagonist SB224289 (Table 3), suggesting that
sumatriptan simultaneously stimulates a systemic vasodilator
and vasoconstrictor mechanism, of which the latter is
amenable to blockade by SB224289. The sumatriptan-induced
systemic dilatation may involve sympathoinhibition mediated
by the 5-ht1F receptor, for which SB224289 displays a very low
and GR127935 only a moderate anity (see Table 1); this
possibility requires further investigation. Whatever the
mechanism, this eect of sumatriptan is clinically of little
relevance. Sumatriptan (MacIntyre et al., 1993) as well as other
similar drugs such as rizatriptan (Sciberraset al., 1997),
alniditan (Goldstein et al., 1996) and zolmitriptan (Seaber et
al., 1996) produce increases rather than decreases in blood
pressure in humans.
Carotid haemodynamics
Sumatriptan decreased total carotid blood flow, mainly due to
a potent vasoconstrictor action on the cephalic arteriovenous
anastomoses. The eect was similar to that observed earlier
with this antimigraine agent (Den Boer et al., 1991; De Vries et
al., 1996). In animals treated with 1 mg kg71 of the 5-HT1B
receptor ligand SB224289, the sumatriptan-induced decreases
in total carotid and carotid arteriovenous anastomotic blood
flow were not much aected; only at 300 mg kg71 of
sumatriptan a significant attenuation was observed (see Figure
1). However, as described above, in the presence of SB224289
an enhancement of the sumatriptan-induced hypotension was
observed. The latter will decrease the carotid perfusion
pressure and, consequently, may exaggerate decreases in blood
flow, thereby masking possible inhibition of the sumatriptan-
induced eects by SB224289. Indeed, the decreases in total
carotid and carotid arteriovenous anastomotic conductance
(where the changes in blood flow are corrected for changes in
blood pressure) were potently antagonized, although not
completely eliminated, in animals treated with 1 mg kg71
SB224289 (Figure 3). In contrast, 1 mg kg71 of the 5-HT1
receptor antagonist BRL15572 did not aect the carotid
vascular eects of sumatriptan in any way. As SB224289 and
BRL15572 display similar anities at their respective receptors
(Table 1), the lack of inhibitory eects by BRL15572,
combined with the potent blockade by SB224289 at similar
doses, it is reasonable to assume that 5-HT1B, but not 5-HT1D
receptors, are involved in the vasoconstriction of carotid
arteriovenous anastomoses. Admittedly, this conclusion is
based on the assumption that species dierences between the
binding of SB224289 and BRL15572 to porcine and human
5-HT1B and 5-HT1D receptors do not play a major role.
Since a part of the sumatriptan-induced carotid arteriove-
nous anastomotic constriction persisted after 1 mg kg71 of
SB224289, it may suggest that other receptors/mechanisms
may be involved. Notwithstanding, we have previously shown
that 0.5 mg kg71, but not 0.25 mg kg71 of the 5-HT1B/1D
receptor antagonist GR127935 was needed for a complete
blockade of the sumatriptan-induced porcine carotid vasocon-
strictor eects (De Vries et al., 1996). In view of the 10 fold
higher anity displayed at the h5-HT1B receptor by GR127935
compared to SB224289 (Table 1), it can be expected that
higher doses of SB224289 are needed to bring about a
complete blockade. Indeed, 3 mg kg71 of SB224289
completely abolished all sumatriptan-induced carotid vascular
eects. In keeping with this, we have previously shown that 3 –
10 fold higher concentrations of SB224289 (De Vries et al.,
1998a) than GR127935 (Villalo´n et al., 1996) were required to
completely inhibit the canine external carotid vasoconstriction
by sumatriptan.
In order to ascertain the specificity of SB224289
(3 mg kg71), we decided to study cardiovascular responses to
noradrenaline before and after administration of the antago-
nist. As expected, noradrenaline produced short-lasting
increases in mean arterial blood pressure, which were
accompanied by increased heart rate, as the baroreflex
mediated bradycardia was absent due to vagotomy (see
Homan & Lefkowitz, 1996). Moreover, noradrenaline
increased carotid blood flow, which was mainly due to the
hypertensive eect, as carotid vascular conductance did not
change in response to the drug, as shown earlier (Verdouw et
al., 1984). SB224289 did not attenuate these eects; in fact, the
noradrenaline-induced hypertension was potentiated, probably
resulting in an enhancement of the increases in carotid blood
flow. Therefore, it is concluded that 3 mg kg71 of SB224289
most likely produced a specific antagonism against the
sumatriptan-induced eects. In keeping with this, SB224289
displays low anities at a- and b-adrenoceptors (Gaster et al.,
1998).
Taking the above into account, the present results imply
that sumatriptan constricts porcine arteriovenous anastomoses
primarily via the 5-HT1B receptor, which in contrast to the 5-
HT1D receptor is abundantly expressed on vascular smooth
muscle (Ullmer et al., 1995; Bouchelet et al., 1996; Longmore
et al., 1997). Moreover, the results obtained in this study imply
that the so-called 5-HT1-like receptor mediating vascular
smooth muscle contraction (Saxena et al., 1998), including
porcine carotid arteriovenous anastomotic constriction (Den
Boer et al., 1991), is most likely to be identical to the 5-HT1B
receptor. This is also shown in the isolated human temporal
artery (Verheggen et al., 1998) and the canine external carotid
vascular bed (De Vries et al., 1998a). Additionally, in view of
the complete blockade by SB224289 and the highly selective
nature of the compound, it seems unlikely that the other
known 5-HT1 subtypes (5-HT1A, 5-ht1E and 5-ht1F) are
involved in the sumatriptan-induced carotid vascular eects.
Thus, intracarotid infusions of LY344864 (1 – 3100 mg min71),
a selective 5-ht1F receptor agonist (Phebus et al., 1997), does
not produce vasoconstriction in the canine external carotid
vascular bed (Villalo´n et al., 1999). Also, mRNAs for 5-HT1A
and 5-ht1E receptor have not been detected in the vascular
smooth muscle (Ullmer et al., 1995).
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In conclusion, the results of the present experiments show
that the constriction of porcine carotid arteriovenous
anastomoses by the 5-HT1 receptor agonist sumatriptan,
being antagonized by the selective 5-HT1B receptor antagonist
SB224289, but not by the 5-HT1D receptor ligand BRL15572,
is predominantly mediated by 5-HT1B receptors. In view of
the putative pathophysiological role of arteriovenous
anastomotic dilatation in migraine (see Heyck, 1969; Saxena,
1995), the constriction of these nonnutrient vessels by
sumatriptan via a 5-HT1B receptor mechanism may be, at
least partly, responsible for the therapeutic eect of the drug
in migraine.
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